Acelyrin (NASDAQ:SLRN) shares closed with a 54% loss yesterday and are currently trading more than 19% lower intra-day today due to disappointing results from a clinical trial of its lead product, izokibep. This medication was developed for individuals with hidradenitis suppurativa (HS), a chronic inflammatory skin condition.

Despite the trial's overall failure to achieve statistical significance, Acelyrin's founder and CEO, Shao-Lee Lin, emphasized some positive aspects. Lin pointed out that izokibep appears to be demonstrating consistent and substantial early responses in patients suffering from hidradenitis suppurativa, all without any safety or tolerability concerns.